Phase 1c study of MV-012-968 in sero-negative infants and young children
Latest Information Update: 27 Jan 2021
At a glance
- Drugs MV 012 968 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Meissa Vaccines
- 27 Jan 2021 New trial record
- 21 Jan 2021 According to a Meissa Vaccines media release, the company expect to initiate this study in the first half of this year.